BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17020973)

  • 1. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
    Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
    Tanwar MK; Gilbert MR; Holland EC
    Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
    Hottinger AF; Iwamoto FM; Karimi S; Riedel E; Dantis J; Park J; Panageas KS; Lassman AB; Abrey LE; Fleisher M; Holland EC; DeAngelis LM; Hormigo A
    Ann Neurol; 2011 Jul; 70(1):163-9. PubMed ID: 21391238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
    Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
    Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
    Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
    Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S
    Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV; Johansen JS; Price PA
    Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
    Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
    Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma YKL-40: a potential new cancer biomarker?
    Johansen JS; Schultz NA; Jensen BV
    Future Oncol; 2009 Sep; 5(7):1065-82. PubMed ID: 19792974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
    Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
    Horbinski C; Wang G; Wiley CA
    Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndrome.
    Kastelijn EA; van Moorsel CH; Ruven HJ; Korthagen NM; Kwakkel-van Erp JM; van de Graaf EA; Zanen P; van Kessel DA; Grutters JC
    Sarcoidosis Vasc Diffuse Lung Dis; 2013 Mar; 30(1):28-35. PubMed ID: 24003532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.